Related Experiment Video
Updated: May 23, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Impact of food administration on lopinavir-ritonavir bioequivalence studies
M Ibarra1, P Fagiolino, M Vázquez
1Center of Bioavailability and Bioequivalence for Medicine Evaluation, University of the Republic, Uruguay.
Abstract:
A bioequivalence study in 16 Caucasian healthy volunteers (eight male, eight female), comparing plasma drug concentrations after a single oral dose of lopinavir and ritonavir (400 and 100mg, respectively), was carried out following a two-period, two-sequence, two-treatment, randomized crossover design. Formulations were given 15 min after a moderate-fat breakfast in order to diminish both the intrinsic highly-variable performance and the sex differences observed in bioequivalence trials under fasting conditions. Ninety percent confidence intervals for the Test/Reference (T/R) ratio of geometric means for area under concentration-time curve (AUC) and maximum concentration (C(MAX)), either for lopinavir or ritonavir, were within the range of 0.80-1.25. Coprandial administration of formulations not only reduced the number of subjects required for bioequivalence assessment, reducing both ethical and economic cost of the trial, but also the sex differences in the T/R ratio of means.
Related Concept Videos
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability Study Design: Absolute Versus Relative Bioavailability
Modified-Release Drug Delivery Systems: Bioavailability
Bioequivalence studies: Biowaivers
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

